S-Doxazosin
Latest Information Update: 11 Jul 2007
Price :
$50 *
At a glance
- Originator Sepracor
- Class Piperazines; Vasodilators
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 24 Jan 2001 Phase-II clinical trials for Benign prostatic hyperplasia in USA (Unknown route)
- 16 Mar 2000 Phase-I clinical trials for Benign prostatic hyperplasia in USA (Unknown route)
- 15 Jun 1998 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)